{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-093906","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2025-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.860084+00:00","generated_at":"2026-05-18T09:28:37.329142+00:00","sec_items":["3.02"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Beam Therapeutics acquires early-stage life sciences company for 403k shares plus up to $89M milestones","bullets":["Upfront consideration: 403,128 shares of BEAM common stock (~$6.86M based on $17.01 close).","Earnout: up to $89M in development, clinical, and commercial milestones, payable in cash or stock at Beam's discretion.","If milestones paid in stock, maximum issuable shares ~5.23M based on $17.01 closing price.","Shares issued as unregistered securities under Section 4(a)(2) exemption.","Target is an early-stage life sciences company; name not disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-093906","json":"https://secwatch.observer/filing/0000950170-25-093906.json","markdown":"https://secwatch.observer/filing/0000950170-25-093906.md","text":"https://secwatch.observer/filing/0000950170-25-093906.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025093906/0000950170-25-093906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025093906/beam-20250701.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:28:37.329142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}